Literature DB >> 27009487

Alternative splicing directs two IL-20R2 isoforms and is responsible for the incomplete gene knockout via the exon I ablation.

H Zhou1, X Liu1, R Yu1, T Long1, R Zhao1, H Liu1, Y Xu1, J G Liang2, P Liang1,2,3,4.   

Abstract

Two heterodimeric receptors consisting of interleukin (IL)-20R2 are shared by three of the IL-20 family of cytokines, IL-19, IL-20 and IL-24. Along with IL-22, these cytokines are downstream effectors of IL-23 and have been implicated in keratinocyte functions and the pathogenesis of psoriasis. Surprisingly, whereas knocking out either the IL-23 or IL-22 gene abolished imiquimod-induced psoriatic phenotypes in mice, similar attempt for IL-20R2 had little effect. Here, we report that the apparent disparity may result from a new IL-20R2 isoform encoded by an alternatively spliced transcript which survived the previous attempt for IL-20R2 gene knockout via the exon I deletion.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27009487     DOI: 10.1038/gene.2016.13

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  28 in total

1.  Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta ) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes.

Authors:  S V Kotenko; L S Izotova; O V Mirochnitchenko; E Esterova; H Dickensheets; R P Donnelly; S Pestka
Journal:  J Biol Chem       Date:  2000-10-16       Impact factor: 5.157

2.  A protocol for differential display of mRNA expression using either fluorescent or radioactive labeling.

Authors:  Peng Liang; Jonathan D Meade; Arthur B Pardee
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

3.  IL-24 transgenic mice: in vivo evidence of overlapping functions for IL-20, IL-22, and IL-24 in the epidermis.

Authors:  Miao He; Peng Liang
Journal:  J Immunol       Date:  2010-01-08       Impact factor: 5.422

4.  Interleukin 20: discovery, receptor identification, and role in epidermal function.

Authors:  H Blumberg; D Conklin; W F Xu; A Grossmann; T Brender; S Carollo; M Eagan; D Foster; B A Haldeman; A Hammond; H Haugen; L Jelinek; J D Kelly; K Madden; M F Maurer; J Parrish-Novak; D Prunkard; S Sexson; C Sprecher; K Waggie; J West; T E Whitmore; L Yao; M K Kuechle; B A Dale; Y A Chandrasekher
Journal:  Cell       Date:  2001-01-12       Impact factor: 41.582

Review 5.  New insights of T cells in the pathogenesis of psoriasis.

Authors:  Yihua Cai; Chris Fleming; Jun Yan
Journal:  Cell Mol Immunol       Date:  2012-06-18       Impact factor: 11.530

6.  Mechanism of pathogenesis of imiquimod-induced skin inflammation in the mouse: a role for interferon-alpha in dendritic cell activation by imiquimod.

Authors:  Azumi Ueyama; Mina Yamamoto; Kenichiro Tsujii; Yoko Furue; Chihiro Imura; Michitaka Shichijo; Kiyoshi Yasui
Journal:  J Dermatol       Date:  2014-01-03       Impact factor: 4.005

7.  Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death.

Authors:  M T Wiekowski; M W Leach; E W Evans; L Sullivan; S C Chen; G Vassileva; J F Bazan; D M Gorman; R A Kastelein; S Narula; S A Lira
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

Review 8.  The IL-20 subfamily of cytokines--from host defence to tissue homeostasis.

Authors:  Sascha Rutz; Xiaoting Wang; Wenjun Ouyang
Journal:  Nat Rev Immunol       Date:  2014-12       Impact factor: 53.106

9.  IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis.

Authors:  Jason R Chan; Wendy Blumenschein; Erin Murphy; Caroline Diveu; Maria Wiekowski; Susan Abbondanzo; Linda Lucian; Richard Geissler; Scott Brodie; Alexa B Kimball; Daniel M Gorman; Kathleen Smith; Rene de Waal Malefyt; Robert A Kastelein; Terrill K McClanahan; Edward P Bowman
Journal:  J Exp Med       Date:  2006-10-30       Impact factor: 14.307

10.  First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti-IL-20 Monoclonal Antibody in Patients with Psoriasis.

Authors:  Alice B Gottlieb; James G Krueger; Mia Sandberg Lundblad; Marie Göthberg; Brett E Skolnick
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

View more
  2 in total

Review 1.  Alternative splicing isoforms in health and disease.

Authors:  Hyoung Kyu Kim; Michael Huy Cuong Pham; Kyung Soo Ko; Byoung Doo Rhee; Jin Han
Journal:  Pflugers Arch       Date:  2018-03-13       Impact factor: 3.657

2.  Alternative splicing and cancer: a systematic review.

Authors:  Yuanjiao Zhang; Jinjun Qian; Chunyan Gu; Ye Yang
Journal:  Signal Transduct Target Ther       Date:  2021-02-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.